Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)

Market Cap	6.31B +0.5%
Revenue (ttm)	1.19B +12.4%
Net Income	194.92M +45.2%
EPS	1.76 +46.8%
Shares Out	109.28M
PE Ratio	32.87
Forward PE	n/a
Dividend	0.19 (0.32%)
Ex-Dividend Date	Jun 29, 2026

Volume	1,968,963
Open	59.00
Previous Close	57.61
Day's Range	56.66 - 59.50
52-Week Range	46.68 - 86.50
Beta	-0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About SHA:688621

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; oncology, metabolic diseases, respiratory tract drug delivery and topical prepara...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2009
• Employees: 1,335
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688621

Financial Performance

In 2025, SHA:688621's revenue was 1.22 billion, an increase of 13.33% compared to the previous year's 1.08 billion. Earnings were 203.87 million, an increase of 14.91%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 29, 2026

Data Sources Report a data error